作者的详细信息

Капланов, Камиль Даниялович

期 栏目 标题 文件
卷 10, 编号 4 (2008) Articles Rekomendatsii po obsledovaniyu i lecheniyu bol'nykh V-kletochnym khronicheskim limfoleykozom
卷 16, 编号 2 (2014) Articles The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
卷 21, 编号 4 (2019) CLINICAL ONCOLOGY The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
卷 22, 编号 1 (2020) CLINICAL ONCOLOGY ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution PDF
(Rus)
卷 22, 编号 2 (2020) Guidelines Hodgkin's lymphoma PDF
(Rus)
卷 22, 编号 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic PDF
(Rus)
卷 22, 编号 2 (2020) Conference Proceedings New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas PDF
(Rus)
卷 23, 编号 1 (2021) CLINICAL ONCOLOGY Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas PDF
(Rus)
卷 23, 编号 2 (2021) CLINICAL ONCOLOGY The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review PDF
(Rus)
卷 23, 编号 3 (2021) CLINICAL ONCOLOGY ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia PDF
(Rus)

##common.cookie##